Molnupiravir (Lagevrio ® ) is an antiviral medication to treat mild to medium COVID-19 infection. Molnupiravir is actually a prodrug of the active substrate N4 -hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction. Molnupiravir and its active agent β-d-N4 -hydroxycytidine can be separated by using a YMC-Triart C18 column and a MS compatible mobile phase at pH 4.3 and relatively mild temperatures of 40°C.
>> Download the Application Note as a PDF
Newsletters
Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.
